| Entry |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Rivaroxaban (JAN/USAN/INN); Xarelto (TN) | ||||||||||||
| Product | XARELTO (A-S Medication Solutions), XARELTO (A-S Medication Solutions), XARELTO (A-S Medication Solutions), XARELTO (A-S Medication Solutions), XARELTO (Cardinal Health 107), XARELTO (Janssen Pharmaceuticals) | ||||||||||||
| Formula | C19H18ClN3O5S | ||||||||||||
| Exact mass | 435.0656 | ||||||||||||
| Mol weight | 435.8813 | ||||||||||||
| Structure |  | ||||||||||||
| Class | Blood modifier agent DG01950 Antithrombotic agent DG01662 Factor Xa inhibitor Metabolizing enzyme substrate DG02954 CYP2J2 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate Transporter substrate DG01665 ABCB1 substrate DG01913 ABCG2 substrate | ||||||||||||
| Remark |
| ||||||||||||
| Efficacy | Antithrombotic, Factor Xa inhibitor | ||||||||||||
| Comment | Prophylaxis of venous thromboembolism | ||||||||||||
| Target | F10 [HSA:2159] [KO:K01314] | ||||||||||||
| Pathway |
| ||||||||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576], CYP2J2 [HSA:1573] Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429] | ||||||||||||
| Interaction | |||||||||||||
| Structure map |
| ||||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] B BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS B01A ANTITHROMBOTIC AGENTS B01AF Direct factor Xa inhibitors B01AF01 Rivaroxaban D07086 Rivaroxaban (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Blood Products and Modifiers Anticoagulants Factor Xa Inhibitors, direct Rivaroxaban D07086 Rivaroxaban (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 3 Agents affecting metabolism 33 Blood and body fluid agents 333 Anticoagulants 3339 Others D07086 Rivaroxaban (JAN/USAN/INN) Drug groups [BR:br08330] Blood modifier agent DG01950 Antithrombotic agent DG01662 Factor Xa inhibitor D07086 Rivaroxaban Metabolizing enzyme substrate DG02954 CYP2J2 substrate D07086 Rivaroxaban DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D07086 Rivaroxaban Transporter substrate DG01665 ABCB1 substrate D07086 Rivaroxaban DG01913 ABCG2 substrate D07086 Rivaroxaban Target-based classification of drugs [BR:br08310] Enzymes Hydrolases (EC3) Serine peptidases F10 D07086 Rivaroxaban (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D07086 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D07086 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D07086 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D07086 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D07086 Drug transporters D07086 | ||||||||||||
| Other DBs |
| ||||||||||||
| KCF data | ATOM 29 1 O2x O 18.3529 -15.4520 2 C1x C 18.3529 -16.8479 3 C5x C 19.5395 -17.5459 4 N1y N 20.7958 -16.8479 5 C1x C 20.7958 -15.4520 6 C1x C 19.5395 -14.7541 7 C8y C 21.9824 -17.5459 8 C8x C 21.9824 -18.9418 9 C8x C 23.2387 -19.6397 10 C8y C 24.4253 -18.9418 11 C8x C 24.4253 -17.5459 12 C8x C 23.2387 -16.8479 13 N1y N 25.6118 -19.6397 14 O5x O 19.5395 -18.9418 15 C1x C 26.0493 -20.9654 16 C1y C 27.4451 -21.0290 17 O7x O 27.8704 -19.6295 18 C7x C 26.7374 -18.8141 19 O6a O 26.7311 -17.4063 20 C1b C 28.2675 -22.0802 21 N1b N 29.6596 -22.1153 22 C5a C 30.4027 -20.9007 23 C8y C 31.8236 -20.9466 24 O5a O 29.7142 -19.6963 25 S2x S 32.9956 -21.6562 26 C8y C 34.1000 -20.7785 27 C8x C 33.6066 -19.4570 28 C8x C 32.1973 -19.4479 29 X Cl 35.4112 -21.1422 BOND 32 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 4 7 1 8 7 8 2 9 8 9 1 10 9 10 2 11 10 11 1 12 11 12 2 13 7 12 1 14 10 13 1 15 3 14 2 16 13 15 1 17 15 16 1 18 16 17 1 19 17 18 1 20 13 18 1 21 18 19 2 22 16 20 1 #Up 23 20 21 1 24 21 22 1 25 22 23 1 26 22 24 2 27 23 25 1 28 25 26 1 29 26 27 2 30 27 28 1 31 23 28 2 32 26 29 1 |